Precipio, Inc. (PRPO) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, operating through two complementary divisions: pathology services (clinical laboratory testing) and proprietary diagnostic product development. The company utilizes its clinical laboratory operations as a self-funded R&D unit to validate products. This report covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $6.71 million | $4.93 million |
| Gross Profit | $2.73 million | $2.14 million |
| Gross Margin | 41% | 43% |
| Operating Loss | $(1.43) million | $(0.86) million |
| Net Loss | $(1.44) million | $(0.88) million |
| Net Loss Per Share (Basic/Diluted) | $(0.81) | $(0.59) |
| Cash and Cash Equivalents | $2.60 million | $1.02 million (end of period) |
| Working Capital | $2.12 million | $2.29 million (Dec 31, 2025) |
| Long-Term Debt (Net) | $0.07 million | $0.08 million |
| Operating Cash Flow | $0.06 million | $(0.04) million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 36% year-over-year, driven primarily by a 63% increase in diagnostic testing cases (4,912 cases in Q1 2026 vs. 3,021 in Q1 2025). Service revenue grew 42%, while product revenue remained flat.
- Margin Compression: Gross margin decreased from 43% to 41%. Management attributes this to a lower average price per case due to a shift in product mix, despite higher volume.
- Expense Increases: Operating expenses rose 38% to $4.15 million. Key drivers included a $0.6 million increase in stock-based compensation, higher sales and marketing personnel costs, and increased R&D supplies.
- Credit Losses: The company recorded a $0.25 million provision for credit losses in Q1 2026, compared to a $0.02 million credit in Q1 2025, reflecting increased reserves for Medicare and third-party payer receivables.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to an accumulated deficit of $104.2 million and reliance on future financing or revenue growth to meet obligations.
- Liquidity: While operating cash flow turned positive ($0.06 million) compared to the prior year, the company notes that recent positive cash flow was aided by non-recurring Employee Retention Credit (ERC) payments of $0.8 million received in 2025. No ERC payments were received in Q1 2026, though $0.7 million remains outstanding.
- Legal and Regulatory: The company is delinquent on certain vendor accounts payable, with some suppliers threatening legal action. Additionally, the company faces standard healthcare regulatory risks regarding fraud and abuse statutes.
- Debt Obligations: The company has a loan from the Connecticut Department of Economic and Community Development (DECD) with a maturity date extended to May 31, 2028.
Investor Verification Checklist
- Going Concern Status: Verify the company's immediate plans for raising capital to address the substantial doubt disclosure and the $104.2 million accumulated deficit.
- Receivables Quality: Review the $1.3 million allowance for credit losses and the concentration of receivables (Customer A represents 34% of receivables) to assess collection risks.
- Vendor Relations: Investigate the status of delinquent accounts payable and potential legal actions from suppliers mentioned in the "Commitments and Contingencies" section.
- ERC Claim: Monitor the status of the remaining $0.7 million Employee Retention Credit claim and the likelihood of its collection.
- Stock-Based Compensation: Note the significant increase in non-cash stock-based compensation ($1.0 million in Q1 2026 vs. $0.4 million in Q1 2025) and its impact on future cash burn if equity issuance is required.